DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.
The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.
2006
Served areaWorldwide
Headcount50
HeadquartersCap Sigma, ZAC Euromédecine II 1682 Rue de la Valsière, 34790 Grabels – France
29,110,552
IPOApril 21, 2010
Stock exchange(s)Euronext Paris